Page 10 - Avestrep2018

Avestrep

Moxifloxacino

Referencias:

1. Informe Anual 2015. Red Hospitalaria de Vigilancia Epidemiológica (RHOVE). Secretaría de
Salud. Primera Edición. México, 2016. Disponible en: www.epidemiologia.salud.gob.mx 2. Bratzler
DW, Dellinger EP, Olsen KM, et al. Clinical practice. guidelines for antimicrobial prophylaxis in
surgery. Am J Health Syst Pharm. 2013;70(3):195-283. 3. Guía Sanford de terapia antimicrobiana
2016. 4. Información para prescribir de Avestrep . 5. Leone M, Albanèse J, Sampol-Manos E, et al.
®
Moxifloxacin penetration in bronchial secretions of mechanically ventilated patients with pneumonia.
Antimicrob Agents Chemother. 2004;48(2):638-40. 6. Singh R, Jadeja RN, Thounaojam MC, et al.
Synthesis, DNA binding and antiproliferative activity of ternary copper complexes of moxifloxacin

and gatifloxacin against lung cancer cells. Inorganic Chemistry Communications. 2012;23:78-84. 7. Zhu
L, Wang N, Yang W, et al. Population pharmacokinetics of intravenous moxifloxacin 400 mg once-
daily dosage in infected patients. J Infect Chemother. 2014;20(10):621-6. 8. Chuchalin A, Zakharova
M, Dokic D, et al. Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis:
a prospective, multicenter, observational study (AVANTI). BMC Pulm Med. 2013;13:5. 9. Kuzman I, Bezlepko
A, Kondova Topuzovska I, et al. Efficacy and safety of moxifloxacin in community acquired pneumonia:
a prospective, multicenter, observational study (CAPRIVI). BMC Pulm Med. 2014;14:105.
10. Lee Y, Park YJ, Kim MN, et al. Multicenter study of antimicrobial susceptibility of anaerobic bacteria
in Korea in 2012. Ann Lab Med. 2015;35(5):479-86. 11. Dalhoff A. Comparative in vitro and in vivo
activity of the C-8 methoxy quinolone moxifloxacin and the C-8 chlorine quinolone BAY y 3118. Clin
Infect Dis. 2001;32 Suppl 1:S16-22.

Avestrep®, alta potencia bactericida